Biotech

Patent law just took another turn, as the Federal Circuit Court has made it more difficult to prove willful infringement - and apparently, ignorance of the law is an excuse. According to Guest Columnist David De Bruin, an attorney and partner with Michael Best &...

Stratatech Corp., a Madison company that is developing a treatment for chronic skin ulcers, has secured a $1.45 million grant from the National Institute on Aging. The money will be used to further develop the company's skin-tissue product, which promotes wound healing by stimulating the...

Platypus Technologies has formally introduced its long-awaited cell migration assay into the research market. The Madison-based company, which employs a combination of biotechnology and nanotechnology to develop research tools, hopes to capture 15 to 20 percent of the $35 million national cell migration market. ...

In a round led by the Appleton-based New Capital Fund, three Wisconsin investment groups have invested an undisclosed amount of money in PercipEnz Technologies, a Madison company that develops clinical research software. PercipEnz, which will use the funding to fill key positions in support of...

The recent assertions of John Simpson, stem cell project director for an organization that is challenging stem cell patents held by the Wisconsin Alumni Research Foundation, ignore some fundamental truths about publicly funded research in Wisconsin, according to columnist Tom Still. In this edition of...

Amgen, once a darling of the biotechnology industry, apparently has become a victim of its own success and perhaps an excess of legal maneuvering, according to MedTech Futures columnist Ogan Gurel. The company recently announced the layoff of 2,600 workers, about 14 percent of its...

Third Wave Technologies is just fine with a recent Food and Drug Administration announcement on relabeling for the blood thinning drugs Coumadin and Wafarin, which have been linked to adverse drug reactions in emergency room settings. The Madison biotechnology company soon will provide an update...

These are heady days for the Wisconsin biotech industry, as the recent financial success of TomoTherapy and NimbleGen would attest, and the presence of Mentor Corp. at University Research Park would argue, according to Jim Leonhart, executive vice president of the Wisconsin Biotechnology and Medical...